Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma.

Jonasch E, Slack RS, Geynisman DM, Hasanov E, Milowsky MI, Rathmell WK, Stovall S, Juarez D, Gilchrist TR, Pruitt L, Ornstein MC, Plimack ER, Tannir NM, Rini BI
J Clin Oncol. 2018 36 (16): 1588-1593

PMID: 29641297 · PMCID: PMC6804828 · DOI:10.1200/JCO.2017.77.1485

MeSH Terms (14)

Administration, Oral Aged Aged, 80 and over Antineoplastic Agents Carcinoma, Renal Cell Drug Administration Schedule Female Humans Kidney Neoplasms Male Middle Aged Sunitinib Surveys and Questionnaires Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities: